The Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer – Cancer Therapy Advisor
Cancer Therapy Advisor |
The Role of Anti-PD-1 Immunotherapy in Advanced Triple-negative Breast Cancer
Cancer Therapy Advisor Various factors predictive of patient outcomes and response to antiprogrammed death-1 (PD-1)/programmed-death ligand-1 (PD-L1) have been identified in the context of advanced breast cancer, according to an oral presentation delivered at the 35th Annual … How Reliable is PD-L1 Expression as a Predictor of Immune Response? |
